The resistance to HPV vaccine research and development results achieved breakthrough stage in our country

08:57 March 22, 2016

Source: People's Daily online - health channel

People in Beijing on March 22 (xinhua yuan yuan cui) recently, the reporter from the national "863" plan project mE6 delta/mE7 TBhsp70 delta vaccine research symposium, according to our country "the human papilloma virus (HPV) fusion protein vaccine" major progress was made in research and development, this symbolized our country in the field of resistance to the HPV vaccine research in the world's leading ranks.

Human papillomavirus (HPV) is a kind of papovavirus cavitation papilloma virus, is a spherical virus DNA. HPV infection has become the world second only to the AIDS virus (HIV), located in the second place of infectious disease harm human health. It is understood that caused by HPV virus disease in patients with more than 50 million people.

At present, the HPV virus has been found that more than 100 genes, divided into two categories: high risk and low risk. More than 40 genotypes, high-risk pattern can cause cervical cancer, esophageal cancer, gastric cancer and so on dozens of tumor; Low-risk type represented by HPV6, 11, can cause of male and female reproductive system and crissum pointed condyloma. The study found that most of the tumor recurrence and metastasis are associated with HPV.

The relevant ministries and commissions of the symposium, evaluation experts, relevant experts to the results of scientific research institutes are introduced: the human papilloma virus fusion protein vaccine mE6 delta/mE7 TBhsp70 delta, by the Chinese academy of medical sciences tumor research institute, Shanghai life science research institute of Chinese academy of sciences and other domestic scientific research institutes and a number of dozens of experts and research workers to participate in, after more than ten years research and development research, phased breakthrough. After routine pathology, pharmacology, pharmacokinetics, drug and technology experiment demonstration, efficient expression of engineering strains, clinical trials and industrialization.

Human papilloma virus fusion protein vaccine, is a kind of treatment, prevention, resistance to transfer of malignant tumor vaccine and sexually transmitted diseases (STD), has been through the national ministry of science and technology "863" project audit acceptance, and obtained the national invention patent. The vaccine research and development success, as an HPV tumor cancer and recurrence of cancer metastasis and acuteness wet wart treatment, puts forward a new solution that provides a effective treatment approach for patients.